Prolaio and Kardigan Combination: A New Era of Heart Health Innovation

At Prolaio, our mission has always been to revolutionize cardiovascular care and clinical research through the power of real-world patient data, advanced analytics, and cutting-edge technology. Today, we’re excited to announce that Prolaio has been acquired by Kardigan, a heart health company modernizing cardiovascular (CV) drug development. This combination will enable us to accelerate the impact of our software and bring more effective, accessible cardiovascular treatments to patients around the world.

Integrating Unmatched Cardiac Intelligence

Prolaio’s high-density data and advanced analytics, combined with Kardigan’s mission to develop multiple targeted medicines in parallel at an unprecedented rate, create a pioneering heart health company to bring people with cardiovascular diseases closer to the cures they deserve. This combination enhances Kardigan’s capabilities to advance its pipeline of late-stage candidates while continuing Prolaio's commitment to providing cutting-edge insights and tools for clinical research and healthcare providers.

Tassos Gianakakos, co-founder of both Prolaio and Kardigan, emphasizes:

“Kardigan and Prolaio were both founded to challenge the status quo in cardiology. If we have any shot at radically reducing the time and cost to develop meaningful new medicines and provide better healthcare access and outcomes for patients, we need to fundamentally embrace real-world data and AI-based tools in a way that is fully integrated across R&D. Together, Prolaio and Kardigan are establishing a new heart health company to make this vision a reality.”

What This Means for Our Patients

At Prolaio, our commitment to enhancing patient access and achieving better health outcomes has always guided our mission. We want to assure our patients that this exciting combination with Kardigan will not alter the quality or consistency of the care they receive. Prolaio remains dedicated to providing exceptional patient support, continuing to utilize our FDA-cleared software and leveraging the insights and advancements that have made our services highly effective.

As we grow and evolve through this combination, our fundamental dedication to improving patient access, outcomes, and cardiovascular care remains steadfast. Patients will continue receiving the personalized attention they have come to trust, that over time can be strengthened by an enhanced, data-driven software that has the potential to predict and help clinicians manage cardiovascular conditions with greater precision.

Advancing Cardiology Through Real-World Data

At Prolaio, we believe that meaningful data has the power to transform the pace of drug development and improve patient outcomes. We’re not just a remote patient monitoring solution—we are a tech-enabled software that can enable better clinical trials through high-density data and clinical insights. Our approach helps researchers optimize study design, reduce overhead, and gain more confidence in their results.

Through this combination, we will continue to provide researchers with precision and longitudinal data insights, driving scale, speed, and scientific confidence in clinical research. Our software can allow us to decrease sample size while gaining more diverse insights, increase statistical power, and boost trial confidence. These capabilities may not only accelerate the pace of drug development but also help ensure that treatments are more precisely tailored to individual patient needs.

A New Standard in Cardiovascular Research

The need for innovation in cardiovascular care has never been more pressing. Cardiovascular disease is the leading cause of death globally, and current treatments often fall short in addressing the complexity of this disease. The Prolaio-Kardigan combination establishes a new standard for cardiovascular research and treatment, emphasizing collaboration, data-driven insights, and accelerated innovation—reflecting a modern, integrated approach for the 21st century.

Our software’s unique capabilities can enhance clinical trials and patient engagement, and we’re energized to extend these resources to a wider network of researchers and healthcare providers. By leveraging real-world data and precision-driven insights, we aim to rapidly identify eligible patients, reduce screen-failure rates, and deliver more comprehensive data. This approach will optimize resource allocation and has the potential to help improve clinical decision-making.

What’s Next for Prolaio?

As part of this exciting combination, Prolaio will continue to function independently, while leveraging Kardigan’s operational scale and resources. This will enable us to expand our reach and continue providing valuable data and insights to researchers, biopharma partners, and healthcare providers around the world.

We are incredibly proud of what we’ve achieved so far, and even more excited about what the future holds. Together with Kardigan, we are setting the stage for a new era in heart health innovation—one that is open, collaborative, and focused on improving cardiovascular care and patient outcomes.

Stay tuned for more updates as we continue to break new ground in the fight against cardiovascular disease.

Contacts

• For media inquiries, please contact Kardigan at press@kardigan.bio.
• For Prolaio patient support, please reach out to support@prolaio.com.